That matters because chronic inflammation can damage blood vessels and contribute to high blood pressure
the dosing figures on this page nonetheless describe published laboratory studies and investigational clinical trials only, not a protocol for use
When appropriate, linking to credible external resources, such as Healthcare.pro, can supplement inoffice education and reinforce safe practices
See my full clinical audit of PRL-8-53 here: To view or add a comment, sign in New Special Issue
Patients who switched from tirzepatide to orforglipron maintained a mean 74.7% of their body weight reduction from the SURMOUNT-5 trial compared with those in the placebo group, which maintained a mean 49.2% of their weight loss
Liu L, Chen J, Wang C, Chen L, Chen L